Abstract

The Epstein–Barr virus (EBV) is linked to various B-cell lymphomas, including Burkitt lymphoma (BL), classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) at frequencies ranging, by routine techniques, from 5 to 10% of cases in DLBCL to >95% in endemic BL. Using higher-sensitivity methods, we recently detected EBV traces in a few EBV-negative BL cases, possibly suggesting a “hit-and-run” mechanism. Here, we used routine and higher-sensitivity methods (qPCR and ddPCR for conserved EBV genomic regions and miRNAs on microdissected tumor cells; EBNA1 mRNA In situ detection by RNAscope) to assess EBV infection in a larger lymphoma cohort [19 BL, 34 DLBCL, 44 cHL, 50 follicular lymphomas (FL), 10 T-lymphoblastic lymphomas (T-LL), 20 hairy cell leukemias (HCL), 10 mantle cell lymphomas (MCL)], as well as in several lymphoma cell lines (9 cHL and 6 BL). qPCR, ddPCR, and RNAscope consistently documented the presence of multiple EBV nucleic acids in rare tumor cells of several cases EBV-negative by conventional methods that all belonged to lymphoma entities clearly related to EBV (BL, 6/9 cases; cHL, 16/32 cases; DLBCL, 11/30 cases), in contrast to fewer cases (3/47 cases) of FL (where the role of EBV is more elusive) and no cases (0/40) of control lymphomas unrelated to EBV (HCL, T-LL, MCL). Similarly, we revealed traces of EBV infection in 4/5 BL and 6/7 HL cell lines otherwise conventionally classified as EBV negative. Interestingly, additional EBV-positive cases (1 DLBCL, 2 cHL) relapsed as EBV-negative by routine methods while showing EBNA1 expression in rare tumor cells by RNAscope. The relapse specimens were clonally identical to their onset biopsies, indicating that the lymphoma clone can largely loose the EBV genome over time but traces of EBV infection are still detectable by high-sensitivity methods. We suggest EBV may contribute to lymphoma pathogenesis more widely than currently acknowledged.

Highlights

  • These authors contributed : Enrico Tiacci, Stefano LazziThe original version of this article was revised due to a retrospective Open Access order

  • We newly collected ten sporadic Burkitt lymphoma (BL) cases for which the Epstein–Barr virus (EBV) status was unknown; of these, only one case was positive at EBERISH and immunohistochemistry for EBNA1, while nine BL cases were negative for EBNA1 and EBV-encoded RNAs (EBER)

  • In diffuse large B-cell lymphoma (DLBCL) samples, 4 of 34 (12%) samples were positive for EBNA and LMP-1 by immunohistochemistry and for EBER at In situ hybridization (ISH), whereas the remainder were negative for all three markers

Read more

Summary

Objectives

The aim of the present study was to analyse a larger case series of lymphoma entities, some with an established link to EBV (BL, DLBCL, HL, and follicular lymphoma—FL [20, 21]) and some not (T-lymphoblastic lymphomas (T-LL), hairy cell leukemias (HCL) and mantle cell lymphomas (MCL) by using quantitative PCR and droplets digital PCR measurement of EBV genes and micro-RNAs in purified neoplastic cells along with highly sensitive RNAscope ISH assay for EBNA1 mRNA, in addition to routine techniques such as immunohistochemistry for LMP1 and EBER-ISH on whole-tissue sections

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call